Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, InBody Co's Enterprise Value is ₩651,470 Mil.
InBody Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was ₩61,345 Mil. Therefore, InBody Co's EV-to-EBIT ratio for today is 10.62.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, InBody Co's Enterprise Value is ₩651,470 Mil.
InBody Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was ₩70,567 Mil. Therefore, InBody Co's EV-to-EBITDA ratio for today is 9.23.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, InBody Co's Enterprise Value is ₩651,470 Mil.
InBody Co's Revenue for the trailing twelve months (TTM) ended in Jun. 2026 was ₩263,893 Mil. Therefore, InBody Co's EV-to-Revenue ratio for today is 2.47.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, InBody Co's Enterprise Value is ₩651,470 Mil.
InBody Co's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was ₩33,104 Mil. Therefore, InBody Co's EV-to-FCF ratio for today is 19.68.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
InBody Co (XKRX:041830) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
InBody Co's current Enterprise Value is ₩651,470 Mil.
InBody Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩61,345 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
InBody Co's current Enterprise Value is ₩651,470 Mil.
InBody Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩70,567 Mil.
InBody Co's current Enterprise Value is ₩651,470 Mil.
InBody Co's Revenue for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩263,893 Mil.
InBody Co's current Enterprise Value is ₩651,470 Mil.
InBody Co's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩40,150 Mil.
InBody Co's current Enterprise Value is ₩651,470 Mil.
InBody Co's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩33,104 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InBody Co Enterprise Value Related Terms
InBody Co Enterprise Value Historical Data
* Premium members only.
The historical data trend for InBody Co's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XKRX:041830 vs ABT, SYK, MDT: Enterprise Value Comparison
For the Medical Devices subindustry, InBody Co's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InBody Co Enterprise Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, InBody Co's Enterprise Value distribution charts can be found below:
* The bar in red indicates where InBody Co's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
InBody Co's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of ₩651,470 Mil mean?
InBody Co (XKRX:041830) has a Enterprise Value of ₩651,470 Mil as of Sep. 03, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on InBody Co and its competitors.
Is InBody Co's Enterprise Value too high?
InBody Co's current Enterprise Value is ₩651,470 Mil. Overall, InBody Co has a GF Score™ of 88/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does InBody Co's Enterprise Value compare to ABT and SYK?
InBody Co's Enterprise Value of ₩651,470 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Medical Devices & Instruments company?
A good Enterprise Value depends on the Medical Devices & Instruments industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on InBody Co and its competitors. InBody Co's current Enterprise Value is ₩651,470 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InBody Co stock overvalued right now?
Based on GuruFocus' analysis, InBody Co (XKRX:041830) is currently considered Significantly Overvalued. The stock's GF Value™ is ₩35,473.99, compared to a current price of ₩58,900.00 — trading 66% above its estimated fair value. The current Enterprise Value is ₩651,470 Mil. InBody Co's overall GF Score™ is 88/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For InBody Co (XKRX:041830), the current Enterprise Value is ₩651,470 Mil as of Sep. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InBody Co (XKRX:041830) Overvalued in 2026?
Based on GuruFocus' analysis, InBody Co stock appears to be overvalued.
The current stock price of ₩58,900.00 is trading 66% above its estimated GF Value™ of ₩35,473.99.
GuruFocus considers InBody Co to be Significantly Overvalued.
Key valuation signals for XKRX:041830:
Enterprise Value: ₩651,470 Mil
GF Value™: ₩35,473.99 vs. price of ₩58,900.00 (66% above fair value)
No single metric tells the full story. See the XKRX:041830 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InBody Co Ltd is a Korea-based company engaged in the manufacturing and distribution of body composition analyzers. The company mainly produces body composition analyzers under the brand name InBody and Lookin'Body. It's InBody series products include InBody720, InBody570, InBody230, InBody J30, and InBody S10.
88GF Score
Get the complete analysis for XKRX:041830
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKRX:041830 has been successfully added to your 
